Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of carboplatin + paclitaxel with bevacizumab and/or rucaparib in advanced ovarian, primary peritoneal, and fallopian tube cancer
2017-002860-42Phase 2Active
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rucaparib, bevacizumab, paclitaxel and carboplatin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (4 arms), sponsored by Policlinico Gemelli. Primary endpoint: Phase I primary endpoint. Started Nov 2020; status: active.
02
Drugs
rucaparibbevacizumabpaclitaxelcarboplatin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2017-002860-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002860-42.